Held by 7 specialist biotech funds
High Convergence# Signal Note: Avoro Capital Initiates $832.5M Position in argenx Avoro's substantial new position in ARGX likely reflects conviction in efgartigimod's commercial trajectory across multiple indications, particularly generalized myasthenia gravis (gMG) where the drug achieved FDA approval in December 2023 and is now ramping.
AI analyst context — unlock full analysis
# SIGNAL NOTE: OrbiMed initiates $122.8M position in argenx OrbiMed's entry into ARGX signals conviction in the company's near-term catalysts, particularly efgartigimod's expanding label potential (recently approved for generalized myasthenia gravis and in Phase 2/3 for other autoimmune indications) and commercial trajectory. The $122.8M position size from a top-tier healthcare allocator suggests confidence in ARGX's FcRn inhibitor platform penetration and margin profile as these programs advance through late-stage development.
+ 5more — see how much conviction went in
See the Full Story